Objective. Using structured implicit review as the gold standard, this study assessed the sensitivity and specificity of an explicit antipsychotic dose criterion derived from schizophrenia guidelines.
phrenia Patient Outcomes Research Team recommendations management guidelines for acute schizophrenia (e.g. the false positives). This report attempts to address that gap and the American Psychiatric Association guidelines, for by examining the documented reasons for deviation from example, recommend treatment of acute exacerbations of guideline-recommended antipsychotic doses (300-1000 schizophrenia with 300-1000 chlorpromazine milligram equi-CPZE) at hospital discharge for 66 patients with schizovalents (CPZE) per day [10, 12] . However, numerous studies phrenia. Our analyses have implications for both quality have shown that routine prescribing practices often do not assessment and clinical quality improvement efforts. conform to evidence-based recommendations [14] [15] [16] [17] [18] . Therefore, guideline-based performance monitoring and improvement efforts for schizophrenia could initially focus on whether antipsychotic medications are prescribed within Methods recommended dose ranges.
We recently described the development and initial ap-Sample plication of a clinical performance measure that assesses SCHIZOM I dataset adherence to an explicit guideline-based antipsychotic dose
The database for the first validation study of the Schizophrenia criterion for treatment of acute schizophrenia (300-1000
Outcomes Module (SCHIZOM I) [26] was the primary dataset CPZE), and have reported on the measure's accuracy, feasused in this study. The study and database have been described ibility, and predictive validity [18, 19] . It is also important to in detail elsewhere [26, 27] . Briefly, the database includes assess the concurrent validity of any new clinical performance detailed longitudinal information for 160 patients with schizomeasure [20, 21] . In this case, concurrent validity can be phrenia who were recruited into the study during an index assessed by examining how well the explicit dose criterion hospitalization in 1992 or 1993. Patients were recruited from identifies inappropriate medication management as compared the Central Arkansas Veterans Healthcare System Medical with direct assessment of medication management by a Center (47%) and from the Arkansas State Hospital (53%), qualified psychiatrist who has reviewed comprehensive ina state-funded facility run by the Arkansas Division of Mental formation on the patient's clinical status, functioning, and Health Services. All patients met DSM-III-R criteria for past response to medications (implicit review). Implicit review schizophrenia, confirmed using the Structured Clinical Inis commonly the reference standard or 'gold standard' for terview (SCID) for DSM-III-R [28] , and were between 18 validation of explicit quality indicators [20] . Implicit review and 55 years of age. is costly, time consuming, and subject to inter-observer bias [22, 23] ; however, it takes into account clinical details and Exclusion criteria subtleties of care that explicit review cannot consider [24] .
For the present study, we excluded SCHIZOM I patients In structured implicit review (SIR), reviewers are instructed who were participating in double-blind medication studies to base their quality judgments on specific information in (n=5), were admitted primarily for treatment of substance the chart [25] .
abuse rather than schizophrenia (n=16), had been hosIn this report, we examine the sensitivity and specificity pitalized during the entire 6-month follow-up period (n= of a guideline-derived explicit antipsychotic dose criterion in 2), or had incomplete data (n=24). In addition, because comparison with SIR by trained psychiatrists. The explicit there is controversy over methods for converting long-acting criterion for antipsychotic dose can be viewed as a new injectable (depot) medication doses to CPZE, and because 'laboratory test' for inappropriate care, and as with any new the predictive validity of explicit dose criteria has not yet been test, the clinician must be aware of its sensitivity and specificity established for depot prescribing, we excluded all patients who for detecting the condition in comparison to a gold standard were receiving long-acting injectable medications alone or in test. The 'condition' to be addressed in this case is incombination with oral medications (n=47). Data for the appropriate medication management and the 'gold standard' remaining 66 patients were utilized in analyses reported here. is the psychiatrists' consensus SIR rating of appropriateness of medication dose. In this context, a 'positive test' refers to Additional data collection an inappropriate antipsychotic dose, either <300 CPZE or >1000 CPZE. Thus, a patient who was prescribed a dose To facilitate SIR ratings, detailed medication management outside the guideline-recommended dose range and whose and treatment data were abstracted from medical records by care was rated 'inappropriate' by SIR would be considered a a trained, experienced psychiatric nurse practitioner, using true test positive. In contrast, a patient prescribed an out-of-a structured chart-abstraction instrument. The instrument, range dose whose care was rated 'appropriate' by SIR would developed specifically to assess the quality of medication be considered a false positive. management for schizophrenia, examines documentation in In order to understand better how this performance meas-multiple domains, including admission evaluation data, subure works we also conducted a descriptive analysis of the stance abuse history, treatment history, medical history, medfrequency and reasons for deviation from guideline re-ication compliance, side effects, and hospital discharge data commendations. To our knowledge, there is no published (instrument available from corresponding author). The nurse literature on the nature and frequency of common and practitioner also compiled narrative summaries of the treatlegitimate reasons (also called 'acceptable alternatives' [25] ), ment course during hospitalization, including data on medication prescribing, medication response, adverse events, which may account for observed deviations from medication Appropriate: care was reasonable and prudent by the standards of medication management for patients with schizophrenia at the time of the hospitalization (e.g. reason for dose is clear, either appropriate or justified). Appears to be appropriate but lacks documentation: care appears to be reasonable and prudent by the standards of medication management for patients with schizophrenia at the time of the hospitalization (i.e. reason for dose is unclear but is probably appropriate). Appears to be inappropriate but lacks documentation: care appears to be below the standard of a reasonable and prudent practitioner at the time of the hospitalization (e.g. drug dosing outside range without justification). Clearly inappropriate: care was below the standard of a reasonable and prudent practitioner at the time of the hospitalization (i.e. enough information is present to assess case as inappropriate).
patient education and consent, treatment adherence, and clinical situation, but for which there was limited docuother medical problems. Source materials for these narratives mentation concerning the clinical rationale for the antiincluded progress notes, discharge summaries, and medication psychotic dose prescribed. The revised form was piloted on orders and medication administration records. In an effort 20 practice records. Although the resulting SIR form includes to maintain the reliability of this process, the nurse practitioner 12 items rating the appropriateness of various aspects of received extensive training from the first author on abstracting treatment, including medication dose, medication choice, medical records and preparing thorough narrative summaries compliance, and aftercare arrangements, in this report we of the documented treatment course. In addition, initial chart discuss only the item assessing appropriateness of antiabstractions and narrative summaries for 10 cases were psychotic medication dose (Table 1) . reviewed by the first author and compared with source documents for accuracy and completeness. Subsequent spot SIR ratings checks of abstractions and summaries were also performed. Two implicit review-team psychiatrists independently reviewed each patient's chart abstraction and narrative summary SIR form and procedures and completed the corresponding SIR rating form. Afterwards, the psychiatrists met to resolve discrepancies in SIR The implicit review team, three psychiatrists and one pharratings. Raters discussed and reached a consensus rating for macist, developed an SIR rating form for quality of medication patients whose medication dosage was rated appropriate (a management, adapting methods used in other implicit ratings 1 or 2) by one rater but inappropriate (a 3 or 4) by the other. of appropriateness of care [29] [30] [31] . Two types of response
The process of resolving disagreements during these meetings scale were considered for the SIR form items. The first scale involved reviewing the chart abstraction forms and narrative was a five-point Likert-type scale similar to those used in case summaries for each subject with discrepant SIR ratings other implicit review studies [32, 33] , with possible ratings and then carefully applying the explicit dose criterion reincluding clearly inappropriate, possibly inappropriate, equicommended by guidelines. In cases in which antipsychotic vocal, possibly appropriate, and clearly appropriate. Pilot dose varied from the recommended range, reviewers contesting of this scale resulted in a large number of charts being sidered whether that variation was nevertheless acceptable, rated as 'equivocal' due to inadequate documentation of key given the clinical circumstances or given the documentation aspects of the process of care. Subsequently, the implicit of a reason for the unusual dose. To facilitate calculation of review team adopted a four-item response scale that elimsensitivity, specificity, and agreement between raters, SIR inated the equivocal rating [30] and included explicit anchors ratings were dichotomized as appropriate (ratings of 1 or 2) for the ratings of appropriateness (Table 1 ). Ratings of '1' or inappropriate (ratings of 3 or 4). and '4' were used when the quality of medication management with respect to neuroleptic dose was assessed to be clearly Agreement between raters appropriate or inappropriate, respectively, based on the availThe psychiatrists' initial independent SIR ratings were in able information and the clinical situation. The intermediate agreement for 76% (n=50) of the sample and discordant for ratings reflected assessments that appeared to be appropriate or inappropriate based on the available information and the 24% of the total sample (n=16). Agreement between raters was statistically significant according to kappa, but low in magnitude ( =0.25, P<0.03). The percentile agreement is high and the kappa is low due to the low prevalence of inappropriate care [34, 35] . The final consensus rating for the 16 initially discordant ratings agreed with one reviewer's initial (pre-consensus) rating in nine cases and the other reviewer's initial rating in the remaining seven cases, which suggests that there was not a systematic bias among the raters in reaching a consensus-the final rating was equally likely to agree with the initial ratings of the individual rater.
Data analysis
All daily antipsychotic doses were converted to CPZE [12, 36, 37] . We calculated the sensitivity and specificity of the explicit antipsychotic dose criterion in comparison with the consensus SIR ratings of dose appropriateness, as shown in Table 2 . Also, we conducted a descriptive analysis of the Figure 1 Scatterplot of antipsychotic doses at hospital disfalse positive and true positive cases. Before examining the charge by structured implicit review (SIR) ratings. data, we developed a list of reasons why discharge antipsychotic doses might legitimately fall outside the guidelinerecommended range (e.g. prior response to high/low antipsychotic dosages, patient preference). We then reviewed all cases. In this sample, with a 20% 'gold standard' prevalence available data for the 15 false positive cases [dosage <300 of inappropriate care, positive predictive value (PPV) for the (n=9) or >1000 CPZE (n=6) when SIR=appropriate] and explicit criterion was 42.3% (95% CI=23-63%), and the the 11 true positive cases [dosage <300 (n=3) or >1000 negative predictive value (NPV) was 95% (95% CI=83-(n=8) when SIR=inappropriate], and then classified each 99%). in terms of the apparent reasons for out-of-range doses. Figure 1 is a scatter-plot of antipsychotic doses at hospital discharge by the SIR consensus ratings (appropriate or inappropriate). From this chart, the distribution of patients' antipsychotic doses in relation to the guideline-recommended Results range can be seen for both patients who were rated as appropriate or inappropriate by SIR.
Criterion validity
At hospital discharge, the majority of the 66 patients Deviation from guideline-recommended doses included in this study (61%; n=40) were receiving doses within the recommended 300-1000 CPZE range; 18% (n= In 11 of the 15 false positive cases (appropriate by SIR despite out-of-range doses) there was adequate documentation in 12) were receiving antipsychotic doses below the guidelinerecommended range (<300 CPZE), and 21% (n=14) were the medical record of a previous history or current good response to out-of-range doses to justify deviating from receiving doses >1000 CPZE. According to the SIR ratings, antipsychotic dose management was appropriate for 80% guideline-recommended antipsychotic doses. For the remaining four false positive cases, it was clear that the (n=53) of patients and inappropriate for 20% (n=13). As shown in Table 2 , the explicit criterion accurately identified dosage was being titrated in the direction of the guidelinerecommended range, but the patient had requested hospital 84.6% (95% CI=55-98%) of inappropriately managed cases and 71.7% (95% CI=58-83%) of appropriately managed discharge before titration was complete.
For four of the 11 patients who were outside the guideline-important to note that because the explicit dose criterion recommended range and also rated as inappropriate by SIR may result in a systematic overestimate of the extent of (true positives) our descriptive analysis found that the dosage inappropriate dosing, performance reports that presented was increased too rapidly without allowing an adequate only these explicit findings to compare health plans could be amount of time for the patient to respond to a more moderate potentially misleading. When quality indicators are used to dosage. For one of these true positive cases, the patient had compare health plans, it is better to err on the side of complained of side effects from higher doses of the prescribed specificity [42] . antipsychotic. Although this may be an acceptable reason for One way to improve the specificity of the explicit antilowering doses, SIR raters considered the prescribed dose psychotic dose indicator would be to combine it with data (80 CPZE) too low to be appropriate. There was no docu-that reflect justified reasons for deviating from guidelines (i.e. mentation to justify the out-of-range doses for the remaining accepting cases outside the dose range where an appropriate six true positive patient cases.
reason is documented). Although others have noted that there are a number of potentially legitimate reasons to deviate from clinical guideline recommendations in the routine care for particular disorders [25] , we are not aware of any other Discussion studies that have examined the type or frequency of acceptable alternatives to guideline-recommended antipsychotic doses This study assessed the concurrent validity of an explicit for acute schizophrenia treatment. The clinical literature indicator of poor quality care for schizophrenia: prescripsuggests that antipsychotic treatment for schizophrenia using tion of a daily antipsychotic dose outside the guidelinelower-than-recommended doses may be appropriate for recommended range of 300-1000 CPZE at the time of patients with a previous history of good treatment response hospital discharge. Using this guideline-based explicit crito such doses, or for those who suffer from intolerable side terion, medication management was classified as inappropriate effects at higher doses [10] . On the other hand, higher-thanfor 39% of the subjects, a level of non-adherence to dosage recommended antipsychotic doses may be appropriate when guidelines comparable to that reported in other recent studies oral medication is used to supplement depot medication, or of the quality of routine care for schizophrenia [14, 17, 38, 39] .
when multiple trials demonstrate that a patient does not The explicit criterion demonstrated high sensitivity, somewhat respond at recommended doses [10, 43] . Our descriptive lower specificity, modest positive predictive value, and high analysis of the reasons for deviating from guideline renegative predictive value using SIR as the gold standard.
commendations suggests that individual variation in response In order for a quality indicator to be useful it must be to antipsychotic medication may account for a substantial sensitive, that is, it must correctly identify a high proportion proportion of appropriate deviations from guidelineof cases of poor quality. It must also be specific, correctly recommended antipsychotic doses (false positives). Further identifying a high proportion of appropriate care cases.
work is needed to specify acceptable alternatives to guidelineThe finding that the explicit dose criterion is sensitive in recommended doses as well as how often such variation comparison with SIR suggests that it can be used as an occurs. indicator of potentially inappropriate antipsychotic dosing for
The explicit guideline-derived dose criterion that we have patients with schizophrenia. We have previously demonstrated tested here could be applied on a large scale by extracting that this indicator correlates with subsequent symptom outdata from administrative pharmacy databases [19] or by chart comes [18] , and other work has suggested that an explicit review. This approach could be enhanced by incorporating antipsychotic dose criterion be used as a measure of guideline additional electronic or chart review data that reflect acconformance [16, 18, 40] . The indicator's somewhat lower ceptable alternatives to guideline-concordant care [16] . As specificity, on the other hand, means that reliance on the noted by Chen et al. [16] , however, such data are not currently explicit criterion alone would result in a relatively high rate available in administrative databases. To make such an apof false positives, overestimating the extent of inappropriate proach viable in routine quality improvement efforts in the antipsychotic prescribing.
future, a field representing reasons for deviation would be Based on these findings, we suggest that the explicit dose needed in administrative databases. Health systems could also criterion would be useful as part of a two-stage clinical quality focus on improving provider documentation of reasons for assessment or improvement effort. The explicit criterion variation from guideline recommendations so that this type could be used as a screen to identify patients at greatest of data could readily be abstracted via chart review. potential risk of poor quality medication management, in
Another quality improvement approach to apply the explicit order to substantially reduce the number of cases that would dose criterion could involve the use of patient outcomes need to be more intensively evaluated using structured implicit data. Efforts to improve the quality of health care could review or other methods. A two-step sample reduction be enhanced significantly by having such information. For method that uses explicit criteria followed by SIR to assess instance, we could focus quality improvement efforts for quality and direct clinical quality improvement has been antipsychotic dosing on patient cases where dose was not advocated by others [5] , and has been shown to be effective guideline concordant and where outcomes were suboptimal. in a variety of clinical situations [41] . To our knowledge, this
In addition, some patients might be receiving moderate doses is the first report suggesting its utility in evaluating the quality of medication management in schizophrenia. It is also yet still have poor outcomes. For these patients, other factors could be examined (e.g. medication choice, medication com-these standards [20] . Our focus on antipsychotic prescribing for schizophrenia is important because high-quality medpliance, side effects, substance use), and interventions to improve the quality of care could be targeted appropriately. ication management can contribute to positive clinical and functional status outcomes [10, 45] . Study results suggest that However, unless a system of care has an outcomes management system or other approach in place for routinely an explicit guideline-derived antipsychotic dose criterion is sufficiently sensitive to be useful for internal clinical quality collecting patient outcomes data, this approach would be unlikely to be feasible for routine quality assessment and improvement efforts in this area. However, given that the explicit dose criterion was not highly specific, it may not be improvement efforts. As noted above, the best use of the explicit criterion, based on current evidence, would be to use appropriate to use as a stand-alone external quality indicator for reporting and accreditation purposes. Thus, until we can two stages: screening with the explicit dose criterion, followed by SIR of cases that do not meet the criterion.
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